Poland· PL-100122295

Soyfem Forte

A medicinal product containing glycine max seminis extractum siccum, registered in Poland by Biofarm Sp. z o.o..

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedSoyfem ForteATC—REGISTER NO.PL-100122295PACKS LISTED3CHECKEDSeptember 27, 2026

The record

At a glance

URPL (Poland)
Active substance
Glycine max seminis extractum siccum
Manufacturer
Biofarm Sp. z o.o.
Country
Poland (PL)
ATC code
—
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    05909991051914
  • gtin
    05909991051921
  • gtin
    05907695215311

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/aa01befc-1ae8-4be7-9e87-acf4e22b8c95
GET /v1/drugs/aa01befc-1ae8-4be7-9e87-acf4e22b8c95?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "230,8 mg",
  "packaging": "05909991051914 ¦ OTC ¦ 22981\n30 tabl.\n05909991051921 ¦ OTC ¦ 22982\n60 tabl.\n05907695215311 ¦ OTC ¦ 121532\n10 tabl.",
  "substance": "Glycinis seminis extractum siccum 230.8 mg",
  "common_name": "Glycine max seminis extractum siccum",
  "pl_product_id": "100122295",
  "pozwolenie_nr": "10519",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}

See everything about glycine max seminis extractum siccum.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.